Journal of Immunotherapy and Precision Oncology (May 2024)

Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1

  • Anagha Deshpande,
  • Javier Munoz,
  • Vrushali Dabak,
  • Amr Hanbali,
  • Razelle Kurzrock

DOI
https://doi.org/10.36401/JIPO-23-32
Journal volume & issue
Vol. 7, no. 2
pp. 122 – 125

Abstract

Read online

ABSTRACT: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that primarily causes the growth of tumors alongnerves. Additionally, the germline mutations involved in NF1 predispose patients to develop further malignancies. The mainstay initial treatment for these malignancies is surgical removal at diagnosis, although targeted therapies are under evaluation in the relapsed setting. We report a case of malignant peripheral nerve sheath tumor (MPNST), gastrointestinal stromal tumor (GIST), and pheochromocytoma in a patient with NF1 who presented with an infected right shoulder lesion that was confirmed to be spindle cell sarcoma via biopsy. She was treated with antibiotics; however, she rapidly deteriorated and opted for hospice care. NF1 germline mutations increase the risk of patients developing various types of cancer. Recent studies have shown that there is a rolefor using MEK inhibitors such as selumetinib for treating patients with NF1.

Keywords